Clinical Trial Update: Assessment of the Safety and Tolerability of ex Vivo Next-generation Neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) Therapy in Advanced Epithelial Tumors and Immune Checkpoint Blockade (ICB) Resistant Solid Tumors [EARLY_Phase 1]

View source ↗

Summary

An early-phase trial is evaluating the safety and tolerability of ex vivo next-generation neoantigen-selected tumor-infiltrating lymphocyte (TIL) therapy in adv…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Epithelial Tumor
• Malignant Solid Tumor

Drugs mentioned

• Neoantigen-selected tumor-infiltrating lymphocyte (TIL) therapy

Snippet

Sponsor: Vall d'Hebron Institute of Oncology | Conditions: Epithelial Tumors, Malignant, Malignant Solid Tumor | EARLY_Phase 1 | Status: RECRUITING